Nasomaris 1 Mg/Ml (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Nasomaris 1 Mg/Ml, is a topical nasal decongestant presented as a 1 mg/mL nasal spray solution for nasal use. It relieves nasal congestion associated with the common cold, sinusitis and allergic rhinitis in adults and children.

GNH USA supplies Nasomaris 1 Mg/Ml as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride is a topical alpha‑adrenergic nasal decongestant used to reduce swelling of the nasal mucosa.

- Common cold: reduces nasal blockage and improves breathing. - Sinusitis: alleviates congestion linked to sinus inflammation. - Allergic rhinitis: decreases nasal swelling caused by allergen exposure.

Adverse reactions may occur with nasal application of Xylometazoline Hydrochloride.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal passages. - Sneezing or mild epistaxis. - Altered taste or bitter after‑taste. - Headache. - Transient dizziness.

Serious or Rare Side Effects: - Severe nasal bleeding. - Allergic reactions such as rash, itching or anaphylaxis. - Hypertension or marked increase in blood pressure. - Tachycardia or palpitations. - Rebound congestion (rhinitis medicamentosa) after prolonged use. - Vision disturbances.

Before using Nasomaris, consider the following safety measures.

- Age restriction: avoid use in children under 6 years unless directed by a healthcare professional. - Pregnancy: safety not established; consult a physician before use. - Cardiovascular disease: use with caution in patients with hypertension or heart disease. - Concomitant decongestants: do not combine with other nasal or oral decongestants to prevent excess vasoconstriction. - Duration of therapy: limit use to 3‑5 days to avoid rebound congestion. - Store at room temperature: keep in the original container, protect from moisture and heat.

Xylometazoline may interact with other medicines; monitor as indicated.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis due to additive vasoconstriction. - Systemic sympathomimetics (e.g., pseudoephedrine): may cause excessive cardiovascular stimulation. - Beta‑blockers: can blunt the intended vasoconstrictive response.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: nasal decongestant may reduce their effectiveness. - Tricyclic antidepressants: possible additive cardiovascular effects. - Other nasal sprays (e.g., steroids): monitor for local irritation or increased systemic absorption.